Moderna, Inc.

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.












The submission of this form does not create an attorney-client relationship.

Investigation Details

Moderna issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.” The Company’s press release indicated a vaccine efficacy of only 78.7%. Following this news, Moderna’s stock price fell over 6% on May 31, 2024.